Evaluation of the predictive value of topoisomerase II α in patients with breast carcinoma

Polish Journal of Pathology

Volumn 60, Issue 3, 2009, Pages 115-123

  Hajduk, Magdalena ^a   Olszewski, Wojciech P ^b   Śmietana, Anetta ^a  

^a Diagnostic Centre PATOLOG   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Breast carcinoma; Topoisomerase II

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; EVALUATION; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951643335     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Binaschi M, Bigioni M, Cipollone A, et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 2001; 1: 113-130.
2. Binaschi M, Capranico G, Dal Bo L, et al. Relationship between lethal effects and topoisomerase II-mediated double-stranded DNA breaks produced by anthracyclines with different sequence specificity. Mol Pharmacol 1997; 51: 1053-1059.
3. Binaschi M, Farinosi R, Borgetto ME, et al. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines. Cancer Res 2000; 60: 3770-3776.
4. Olszewski WP, Mrozkowiak A, Suszylo K, et al. Oznaczanie statusu genów TOPA 2 i HER 2 w raku piersi metoda̧. fluorescencyjnej hybrydyzacji in situ (FISH). Zakład Patologii Centrum Onkologii w Warszawie. Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej Centrum Onkologii w Warszawie. Program Badań - zadanie wieloletnie 2006.
5. Szulawska A, Czyż M. Molekularne mechanizmy działania antracyklin. Postȩpy Higieny Dośw 2006; 60: 78-100.
6. Bakshi RP, Galande S, Muniyappa K. Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase (review). Crit Rev Biochem Mol Biol 2001; 36: 1-37.
7. Nakopoulou L, Giannopoulou I, Lazaris Ch, et al. The favorable prognostics impact of tissue inhibitor of matrix metalloproteinases - 1 protein overexpression in breast cancer cells. APIMS 2003; 111: 1027-1036.
8. Steward C, Ratain M. Pharmacology of cancer chemotherapy. Topoisomerase interactive agents. In: Principles and Practice in Oncology. De Vita, et al. (eds). Philadelphia 2001; 415-418.
9. Olszewski WP, Mrozkowiak A, Kosińska-Bauer, et al. Coamplification of HER2 and topa 2 alpha genes in selected cases of breast carcinoma. Pol J Pathol 2007; 2: 130.
10. Bhargava R, Lal P, Chen B, et al. HER 2/neu and Topoisomerase II alpha Gene Amplification and Protein Expression in Invasive Breast Carcinomas. Am J Clin Pathol 2005; 123: 889-895.
11. Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of HER 2 status in breast cancer. Br J Cancer 2003; 88: 1587-91.
12. Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER - 2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 2004; 10: 4793-4798.
13. Mueller R. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alfa protein in human breast tumor samples, genes, Chromosomes. Cancer 2004, 39: 288-297.
14. Olsen KE, Knudsen H, Rasmussen BB, et al. and Danish Breast Cancer Cooperative Group: Amplification of HER 2 and TOP 2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004; 43: 35-42.
15. Olszewski WP. HER2 status in breast carcinoma - practical information for physicians. Nowa Medycyna - Badania nad rakiem. 2005; 1.
16. Durbeq V, Leo A, Cardoso F, et al. Correlation between topoisomerase II alpha gene amplification and protein expression in HER 2 amplified breast cancer. Int Oncol 2004; 25: 1473-1479.
17. Jacobson KK, Morrison LE, Henderson BT, et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosomes Cancer 2004; 40: 19-31.
18. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-847.
19. Murphy DS, McHardy P, Coutts J, et al. Interphase cytogenetic analysis of ERBB2 and TOP2A co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 1996; 64: 18-26.
20. Villman K, Stahl E, Liljegren G, et al. TOP 2A and HER 2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncologica 2006; 45: 590-596.
21. Di Leo A, Cardoso F, Durbecq V, et al. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in year 2002. Int J Clin Oncol 2002; 245-253.
22. Di Leo A, Gancberg D, Larsimont D, et al. HER 2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
23. Harris LN, Yang L, Liotcheva V, et al. Induction of topoisomerase II activity after ErbB-2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7: 1497-1504.
24. Śnietura M, Ponikiewska D, Liszka J, et al. Simultaneous assessment of amplification and expression of the ERBB2 and topo 2 alpha genes using FISH and immunohistochemistry in women with breast cancer. Pol J Pathol 2007; 2: 150.
25. Arpino G, Ciocca DR, Weiss H, et al. Predictive value of apoptosis, proliferation HER 2 and topoisomerase II alpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005; 92: 69-75.
26. Cardoso F, Durbecq V, Larsimont D, et al. Correlation between complete response to anthracycline - based chemotherapy and topoisomerase II alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24: 201-209.
27. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061-1067.
28. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning? Clin Breast Cancer 2003; 4: 179-186.
29. Di Leo A, Larsimont D, Gancberg D, et al. HER 2 and topoisomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-1089.
30. Isola JJ, Tanner M, Holli K, et al. Amplification of Topoisomerase II Alpha is a Strong Predictor of Response to Epirubicin - Based Chemotherapy in HER-2/neu-Positive Metastatic Breast Cancer. In: San Antonio Breast Cancer Symposium 2000; (abstr 21); 2000 (abstr 21).
31. Järvinen TA, Tanner M, Barlund M, et al. Amplification and Deletion of Topoisomerase II alpha Associate with Erb-2 Amplification and Affect Sensitivity to Topoisomerase II alpha Inhibitor Doxorubicin in Breast Cancer. Am J Pathol 2000; 3: 839-846.
32. Wang JC. Cellular roles of DNA topoisomerases a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440.
33. Hajduk M. Topoisomerase II alpha - a fundamental prognostic factor in breast carcinoma. Pol J Pathol 2009; 2: 67-75.
34. Tavassoli FA, Deville P. Tumors of the Breast and Female Genital Organs. WHO Classification of Tumors, 2003.
35. Hayes DF. Breast cancer. In: Prognostic Factors in Cancer. Gospodarowicz MK (ed.). John Wiley and Sons, New Jersey 2006; 27: 207-212.
36. Turunen N, Karihtala P, Mantyniemi A, et al. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 2004; 112: 123-132.
37. Siedlecki JA. Biologia molekularna nowotworów. In: Onkologia kliniczna. Krzakowski M (ed.). Borgis, Warszawa 2006; 61.
38. Isaacs RJ, Davies SJ, Sandri MI, et al. Physiological regulation of eukaryotic topoisomerase II Biochem Biophys Acta 1998; 1400: 121-137.
39. Järvinen TA, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 77: 2267-2273.
40. Carlsson J, Nordgren H, Sjostrom J, et al. HER 2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004; 90: 2344-2348.
41. Park K, Kim J, Lim S, et al. Topoisomerase II alpha (topo II) and HER 2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003; 39: 631-634.
42. Tanner M, Järvinen P, Isola J. Amplification of HER 2/neu and topoisomerase II? in primary and metastatic breast cancer. Cancer Res 2001; 61: 5345-5348.
43. Jarvinen TA, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase II? and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998; 72: 2267-2273.
44. Mrozkowiak A, Olszewski WP, Suszylo K, et al. The usefulness of fluorescent in situ hybridization (FISH) in the algorithm of diagnosis management in breast cancer. Pol J Pathol 2007; 2: 128.
45. Knoop AS, Knudsen H., Balslev E, et al. Retrospective analysis of topoisometase II alpha amplifications and deletions predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490.
46. Petit T, Wilt M, Veiten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40: 205-211.
47. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
48. Tanner M, Järvinen P, Isola J. Topoisomerase II A Gene amplification Predicts Favorable treatment Response to Tailored and Dose-Escalated Anthracycline - Based Adjuvant Chemotherapy in HER 2/neu - Amplified Breast Cancer. Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2438.